Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1353684 | 0.87 | NOS1 (0.39) | NOS1NOS3NOS2LMNAKMT2A | |
| SCHEMBL28113585 | 0.86 | NOS1 (0.36) | NOS1NOS3NOS2LMNAKMT2A | |
| SCHEMBL7936428 | 0.82 | NOS1 (0.34) | NOS1NOS3NOS2LMNAKMT2A | |
| SCHEMBL5209072 | 0.81 | ALDH1A1 (0.39) | NOS1NOS3NOS2LMNAKMT2A | |
| SCHEMBL16340968 | 0.81 | NOS1 (0.39) | NOS1NOS3NOS2LMNAKMT2A | |
| SCHEMBL221769 | 0.81 | ALDH1A1 (0.39) | NOS1NOS3NOS2LMNAKMT2A | |
| SCHEMBL523836 | 0.79 | DGAT1 (0.41) | NOS1NOS3NOS2LMNAKMT2A | |
| SCHEMBL27549577 | 0.79 | NOS1 (0.35) | NOS1NOS3NOS2LMNAKMT2A | |
| SCHEMBL27572159 | 0.77 | NOS1 (0.37) | NOS1NOS3NOS2LMNAKMT2A | |
| SCHEMBL29019393 | 0.77 | NOS1 (0.39) | NOS1NOS3NOS2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211671-B2 | Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-05-01 | — | — | US | disclosed |
| US-20050075384-A1 | Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-07 | — | — | US | disclosed |
| EP-0078545-B1 | IMIDAZOLECARBOXYLIC ACID DERIVATIVES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-02-03 | — | — | EP | disclosed |
| US-4418071-A | Cardiotonic imidazolecarboxylic acid derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1983-11-29 | — | — | US | disclosed |
| EP-0078545-A1 | Imidazolecarboxylic acid derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1983-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075384-A1 | Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAMTS1, ADAM33, ADAM8 | NOS1 267/4885NOS3 275/4885NOS2 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.